Nitric oxide for the evaluation and treatment of pulmonary hypertension congenital heart disease

Texas Heart Institute Journal

Volumn 24, Issue 4, 1997, Pages 308-316

  Kovalchin, John P ^a   Mott, Antonio R ^b   Rosen, Kerry L ^b   Feltes, Timothy F ^b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

Heart defects, congenital therapy; Hypertension, pulmonary; Nitric oxide; Pulmonary heart disease

Indexed keywords

ACETYLCHOLINE; ARGININE; CIGARETTE SMOKE; CYCLIC GMP; ENDOTHELIUM DERIVED RELAXING FACTOR; HEME; METHEMOGLOBIN; METHEMOGLOBIN REDUCTASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; NITROGEN; NITROGEN DIOXIDE; OXYGEN; OXYHEMOGLOBIN; PEROXYNITRITE;

CONGENITAL HEART DISEASE; CYANOSIS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG VASCULAR RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PULMONARY HYPERTENSION; REVIEW;

ADMINISTRATION, INHALATION; CHILD; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; NITRIC OXIDE; VASODILATOR AGENTS;

EID: 0031416840     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Curran RD, Mavroudis C, Backer CL, Sautel M, Zales VR, Wessel DL. Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension. Ann Thorac Surg 1995;60:1765-71.
2. Beghetti M, Habre W, Friedli B, Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 1995;73:65-8.
3. Wessel DL, Adatia I. Clinical applications of inhaled nitric oxide in children with pulmonary hypertension. Adv Pharmacol 1995;34:475-504.
4. Hoffman JI, Rudolph AM, Heymann MA. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation 1981;64:873-7.
5. Berner M, Beghetti M, Spahr-Schopfer I, Oberhansli I, Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996;77:532-5.
6. Wheller J, George BL, Mulder DG, Jarmakani JM. Diagnosis and management of postoperative pulmonary hypertensive crisis. Circulation 1979;60:1640-4.
7. Friedli B, Kidd BS, Mustard WT, Keith JD. Ventricular septal defect with increased pulmonary vascular resistance. Late results of surgical closure. Am J Cardiol 1974;33:403-9.
8. Bush A, Busst CM, Haworth SG, Hislop AA, Knight WB, Corrin B, et al. Correlations of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. Br Heart J 1988;59:480-5.
9. Anderson TJ, Meredith IT, Ganz P, Selwyn AP, Yeung AC. Nitric oxide and nitrovasodilators: similarities, differences and potential interactions. J Am Coll Cardiol 1994;24:555-66.
10. Cornfield DN, Abman SH. Inhalational nitric oxide in pulmonary parenchymal and vascular disease. J Lab Clin Med 1996;127:530-9.
11. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
12. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
13. Zapol WM, Rimar S, Gillis N, Marietta M, Bosken CH. Nitric oxide and the lung Am J Respir Crit Care Med 1994;149: 1375-80.
14. Ignarro LJ, Buga GM, Byrns RE, Wood KS, Chaudhuri G. Endothelium-derived relaxing factor and nitric oxide possess identical pharmacologic properties as relaxants of bovine arterial and venous smooth muscle. J Pharmacol Exp Ther 1988;246:218-26.
15. Archer SL, Huang JM, Hampl V, Nelson, DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 1994;91: 7583-7
16. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994,368:850-3.
17. 2+ by sarcoplasmic reticulum in vascular smooth muscle. Circ Res 1988;62:961-4.
18. Roberts JD Jr, Chen TY, Kawai N, Wain J, Dupuy P, Shimouchi A, et al. Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circ Res 1993;72:246-54.
19. Oda H, Kusumoto S, Nakajima T. Nitrosyl-hemoglobin formation in the blood of animals exposed to nitric oxide. Arch Environ Health 1975;30:453-6.
20. Chiodi H, Mohler JG. Effects of exposure of blood hemoglobin to nitric oxide. Environ Res 1985;37:355-63
21. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83: 2038-47.
22. Yoshida K, Kasama K. Biotransformation of nitric oxide. Environ Health Perspect 1987;73:201-5.
23. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-4.
24. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:818-9.
25. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20.
26. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Pediatrics 1997;99:838-45.
27. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88:2128-38.
28. Rabinovitch M, Haworth SG, Castañeda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978;58:1107-22.
29. Haworth SG. Pulmonary vascular disease in different types of congenital heart disease. Implications for interpretation of lung biopsy findings in early childhood. Br Heart J 1984; 52:557-71.
30. Rabinovitch M, Bothwell T, Hayakawa BN, Williams WG, Trusler GA, Rowe RD, et al. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest 1986;55:632-53.
31. Meyrick B, Reid L. Ultrastructural findings in lung biopsy material from children with congenital heart defects. Am J Pathol 1980;101:527-42.
32. Rabinovitch M. Morphology of the developing pulmonary bed: pharmacologic implications. Pediatr Pharmacol (New York) 1985;5:31-48.
33. Journois D, Pouard P, Mauriat P, Malhère T, Vouhé P, Safran D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 1994;107:1129-35.
34. Goetzman BW, Sunshine P, Johnson JD, Wennberg RP, Hackel A, Merten DF, et al. Neonatal hypoxia and pulmonary vasospasm: response to tolazoline. J Pediatr 1976;89: 617-21.
35. Artman M, Parrish MD, Boerth RC, Boucek RJ Jr, Graham TP Jr. Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects. Circulation 1984;69:949-54.
36. Pietro DA, LaBresh KA, Shulman RM, Folland ED, Parisi AF, Sasahara AA. Sustained improvement in primary pulmonary hypertension during six years of treatment with sublingual isoproterenol. N Engl J Med 1984;310:1032-4.
37. Damen J, Hitchcock JF. Reactive pulmonary hypertension after a switch operation. Successful treatment with glyceryl trinitrate. Br Heart J 1985;53:223-5.
38. Bixler TJ, Gott VL, Gardner TJ. Reversal of experimental pulmonary hypertension with sodium nitroprusside. J Thorac Cardiovasc Surg 1981;81:537-45.
39. De Feyter PJ, Kerkkamp HJ, de Jong JP. Sustained beneficial effect of nifedipine in primary pulmonary hypertension. Am Heart J 1983;105:333-4.
40. D'Ambra MN, LaRaia PJ, Philbin DM, Watkins WD, Hilgenberg AD, Buckley MJ. Prostaglandin E1. A new therapy for refractory right heart failure and pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg 1985;89:567-72.
41. Miller OI, Celermajer DS, Deanfield JE, Macrae DJ. Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 1994;108:487-94.
42. Gerlach H, Rossaint R, Pappert D, Falke KJ. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993;23:499-502.
43. Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993;87:447-53.
44. Day RW, Lynch JM, Shaddy RE, Orsmond GS. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. Am J Cardiol 1995;75:196-8.
45. Allman KG, Young JD, Carapiet D, Stevens JE, Ostman-Smith I, Archer LN. Effects of oxygen and nitric oxide in oxygen on pulmonary arterial pressures of children with congenital cardiac defects. Pediatr Cardiol 1996;17:246-50.
46. Winberg P, Lundell BP, Gustafsson LE. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease. Br Heart J 1994;71:282-6.
47. Buga GM, Griscavage JM, Rogers NE, Ignarro LJ. Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res 1993;73:808-12.
48. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N EnglJ Med 1993;328:399-405
49. Adatia I, Atz AM, Jonas RA, Wessel DL. Diagnostic use of inhaled nitric oxide after neonatal cardiac operations. J Thorac Cardiovasc Surg 1996;112:1403-5.
50. Houde C, Bohn DJ, Freedom RM, Rabinovitch M. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J 1993;70:461-8.
51. OSHA excursion limits. MMWR August 26,1988;37:S-7(21).
52. Norman V, Keith CH. Nitrogen oxides in tobacco smoke. Nature 1965;205:915-6.
53. Royall JA, Kooy NW, Beckman JS. Nitric oxide-related oxidants in acute lung injury. New Horiz 1995;3:113-22.
54. Higenbottam TW. Inhaled nitric oxide: it is effective, but is it safe? New Horizons 1995;3:7-9.
55. Foubert L, Fleming B, Latimer R, Jonas M, Oduro A, Borland C, et al. Safety guidelines for use of nitric oxide. Lancet 1992; 339:1615-6.
56. Stamler JS. Inhaled nitric oxide as a therapeutic modality: is it good or bad? New Horizons 1995;3:9-11.
57. Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994;149:538-51.
58. Borland CD, Higenbottam TW. A simultaneous single breath measurement of pulmonary diffusing capacity with nitric oxide and carbon monoxide. Eur Respir J 1989;2:56-63.
59. Askew GL, Finelli L, Genese CA, Sorhage FE, Sosin DM, Spitalny KC. Boilerbaisse: an outbreak of methemoglobinemia in New Jersey in 1992. Pediatrics 1994;94:381-4.
60. Fischbach FT. A manual of laboratory diagnostic tests. 3rd ed. Philadelphia: JB Lippincott, 1988:63-5.
61. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-34.
62. Bevilacqua MP, Nelson RM. Selectins. J Clin Invest 1993;91: 379-87.
63. Dawson TM, Dawson VL. ADP-ribosylation as a mechanism for the action of nitric oxide in the nervous system. New Horiz 1995;3:85-92.
64. Cioffi WG Jr, Ogura H. Inhaled nitric oxide in acute lung disease. New Horiz 1995;3:73-85.
65. Kanwar S, Kubes P. Nitric oxide is an antiadhesive molecule for leukocytes. New Horiz 1995;3:93-104.
66. Albina JE, Reichner JS. Nitric oxide in inflammation and immunity. New Horiz 1995;3:46-64.
67. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. New Horiz 1995;3:2-32.
68. Roberts JD Jr, Roberts CT, Jones RC, Zapol WM, Bloch KD. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat. Circ Res 1995;76:215-22.
69. Kolpakov V, Gordon D, Kulik TJ. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995;76:305-9.
70. Mehta S, Stewart DJ, Langleben D, Levy RD. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995;92:1539-45.
71. Baudouin SV, Bath P, Martin JF, Du Bois R, Evans TW. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br J Clin Pharmacol 1993;36:45-9.